Given the demonstrated effectiveness of 2B7 in hepatocellular and pancreatic cancer models, anti-TM4SF4 monoclonal antibody therapy may be broadly applicable to other TM4SF4-overexpressing tumors, supporting the development of universal CSC-targeted cancer therapies. This evidence concerns the gene TM4SF4 and cancer.